Dopaminergic Dysfunction in Late-Life Depression (D3)
Sponsor: Emory University
A PHASE2 clinical study on Cognitive Decline and Depressive Disorder, Treatment-Resistant, this trial is ongoing. The trial is conducted by Emory University and has accumulated 14 data snapshots since 2021. Psychiatric clinical trials are essential for establishing evidence-based treatment standards.
Status Flow
Change History
14 versions recorded-
Feb 2026 — Present [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Sep 2025 — Feb 2026 [monthly]
Recruiting PHASE2
-
Aug 2025 — Sep 2025 [monthly]
Recruiting PHASE2
-
Sep 2024 — Aug 2025 [monthly]
Recruiting PHASE2
-
Aug 2024 — Sep 2024 [monthly]
Recruiting PHASE2
▶ Show 9 earlier versions
-
Jul 2024 — Aug 2024 [monthly]
Recruiting PHASE2
-
Apr 2024 — Jul 2024 [monthly]
Recruiting PHASE2
-
Mar 2024 — Apr 2024 [monthly]
Recruiting PHASE2
-
Apr 2023 — Mar 2024 [monthly]
Recruiting PHASE2
-
Mar 2022 — Apr 2023 [monthly]
Recruiting PHASE2
-
Mar 2021 — Mar 2022 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jan 2021 — Mar 2021 [monthly]
Not Yet Recruiting PHASE2
-
Nov 2020 — Jan 2021 [monthly]
Not Yet Recruiting PHASE2
-
Aug 2020 — Nov 2020 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Emory University
- Rutgers University
- University of North Carolina, Chapel Hill
- University of Pittsburgh
- University of Pittsburgh Medical Center
- Vanderbilt University Medical Center
For direct contact, visit the study record on ClinicalTrials.gov .